Effects of radiotherapy and estramustine on the microvasculature in malignant glioma by Johansson, M et al.
An increasing amount of evidence supports the hypothesis that
tumours are dependent on a sufficient blood supply for their main-
tenance and growth (Folkman, 1971, 1990). Its clinical importance
has been demonstrated by the finding of tumoural neovasculariza-
tion as a negative prognostic factor in a number of tumours
(Weidner, 1993; Gasparini and Harris, 1995). Hypoperfusion of
tumours with resulting hypoxia is considered to be one of the
major causes of radiotherapy failure (Gray, 1961; Littbrand and
Révész, 1969; Hall, 1994). Systemically administered cytotoxic
agents are obviously dependent on the vasculature of the tumour to
reach their target. An impaired tumour vasculature may limit the
amount of drug reaching the blood–tumour interface (Jain, 1987).
In this sense, a high grade of tumour vascularization facilitates the
effects of treatment and, at the same time, paradoxically it implies
a poor prognosis.
Malignant glioma, the most common malignant brain tumour, is
a highly vascularized tumour in which a high grade of neovascu-
larization has been shown to be a negative prognostic factor (Leon
et al, 1996). The prognosis, in spite of surgical resection and radio-
therapy, is poor due to its diffusely infiltrative growth pattern
(Kelly et al, 1987). Estramustine phosphate is a cytotoxic agent
with demonstrated anti-tumoural effects in experimental glioma
models in vitro as well as in vivo (Bergenheim et al, 1994c; von
Schoultz et al, 1988). Its metabolite, estramustine (EaM), has been
demonstrated to enhance the effect of radiotherapy (Bergenheim et
al, 1995), which may be explained by the induced arrest of tumour
cells in G2/M phase of the cell cycle (Yoshida et al, 1994;
Bergenheim et al, 1995) as well as to the demonstrated increase in
glioma blood flow (Johansson et al, 1997).
In this study, we have evaluated the effects of radiotherapy and
EaM on vascularization in malignant glioma using an experi-
mental rat model. We have also studied the effect on the expres-
sion of mRNA for vascular endothelial growth factor (VEGF) as
one of the most important stimulating factors for neovasculariza-
tion (Ferrara, 1996).
MATERIALS AND METHODS
Tumour model
The previously characterized syngenic intracerebral BT4C rat
glioma model was used for this study (Bergenheim et al, 1994a).
Prior to implantation, tumour cells (originally a generous gift from
Prof. Bjerkvig, Bergen, Norway) were suspended in minimal
essential medium (MEM, Flow laboratories, Glasgow, UK) and
supplemented with 5% rat serum. BT4C rat glioma cells were
thereafter transplanted intracerebrally using a stereotactic frame
(Kopf 900, David Kopf, Tujunga, CA, USA). A total of 20 000
tumour cells in a volume of 5 ml were deposited in the caudate
nucleus, 3.5 mm right of bregma and at a depth of 4.5 mm, using a
microsyringe (22G, Unimetrics, Shorewood, IL) fitted to the
micromanipulator of the stereotactic frame. Animals were housed
under controlled conditions and fed ad libitum. The experiments
were approved by the local ethics committee for animal research.
Treatment schedule
A total of 26 rats were divided into four groups after implantation.
Two groups received radiotherapy (n = 7) or EaM (n = 6) alone
and one group received a combination of radiotherapy and EaM
(n = 6). The fourth group served as untreated controls (n = 7).
Since EaM is the most active metabolite to accumulate in glioma
tissue, EaM was used for this study (Bergenheim et al, 1993,
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1994b; Johansson et al, 1998). EaM was dissolved in ethanol and
castor oil (2:8) giving a concentration of 10 mg ml-1. EaM treat-
ment started on day 7 after tumour implantation and was given as
daily 20 mg kg-1 intraperitoneal (i.p.) injections until sacrifice on
day 24. The dose of EaM given was obtained from previous
studies showing that 20 mg kg-1 EaM daily exerts a significant
anti-tumoural action with a low grade of toxicity (Bergenheim et
al, 1994a). Day 24 was chosen for sacrifice since the animals do
not suffer from severe neurological symptoms at this time point
and the untreated tumour size is known to be representative for the
final outcome (Bergenheim et al, 1994a).
Radiotherapy was given as fractionated whole brain irradiation
using a conventional 4 MV linear accelerator. Treatment was
given as daily 4 Gy fractions for 5 consecutive days starting on
day 12 after tumour implantation. Source surface distance was
0.66 m and the dose rate 2 Gy min-1. Irradiation was performed on
conscious rats temporarily immobilized in a net restrainer. The
dose and fractionation was chosen according to previous experi-
ence with the purpose to obtain a moderate tumour effect without
inflicting serious normal brain tissue damage (Henderson et al,
1981; Bergenheim et al, 1995).
Tissue preparation and tumour size assessment
After sacrifice, brains were immediately removed and fixed
overnight in phosphate-buffered 4% formaldehyde solution.
Brains were thereafter kept cold in 70% ethanol until further
analysis was performed. Tumour size was evaluated as volume.
Height and width was measured at the largest coronal section
using a calliper. Tumour volume was thereafter calculated using
the formula for the ellipsoid (r1 ´ r2 ´ r3 ´p´4/3) where the
radius in the sagittal plane was approximated to the same as the
coronal radius. The rat brains were than dehydrated in graded
ethanol series and embedded in paraffin. For morphological
studies, including in situ hybridization, 4-mm sections were cut
using a sledge microtome. Tissue sections were mounted on poly-
lysin-covered microscope slides for immunohistochemistry and on
Super Frost/Plus slides (Histolab, Västra Frölunda, Sweden) for in
situ hybridization.
Vascular staining and microvascular density
Vessels in the BT4C brain tumours were immunohistochemically
stained for factor VIII and quantified manually using a method
originally presented by Weidner (1993). Sections chosen for
immunohistochemical staining were deparaffinized in xylene,
dehydrated in graded ethanol series and washed in deionized
water. The tissue was then permeabilized in 0.05% protease P27 at
37°C for 30 min and the digestion was stopped by immersion in
95% ethanol for 5 min followed by washing in phosphate-buffered
saline (PBS) for 5 min ´ 4. Slides were then incubated with normal
goat serum for 20 min prior to 60-min incubation with rabbit anti-
rat factor VIII antibody (DAKO A/S, Glostrup, Denmark) diluted
1:200. After washing in PBS 5 min ´ 4 slides were incubated with
a biotinylated goat anti-rabbit antibody (Vector laboratories,
Burlingame, CA) and washed in PBS 5 min ´ 4 again. Sections
were subsequently incubated with avidin linked alkaline phospha-
tase (Vector ABC-AP) for 20 min according to the vendors
recommendations. Development was finally performed using
alkaline phosphatase reagent (Vector) diluted in Tris buffer.
Endogenous alkaline phosphatase activity was blocked by adding
1m M Levamisole to the reagent buffer. After 5 min washing in tap
water, slides were briefly immersed in 95% ethanol and mounted
in gelatine glycerol.
Assessment of microvascular density (MVD) was performed by
manual counting in selected areas with high vascular density (hot
spots). Each tumour was scanned at low magnification and four
hot spots were chosen for MVD quantification. All stained objects
within a 200´ field (area 1.227 mm2) were counted using a stan-
dard light microscope (Axiophot, Zeiss, Oberkochen, Germany).
Each hot spot was counted twice and the arithmetical mean in each
spot was used to calculate the mean MVD for each tumour section
which was used for further analysis.
In order to obtain quantitative information on tumour vessel size,
and to validate the manual counting of vessels, the sections were
also analysed using a computerized image analysis system (CIAS).
The system used for obtaining images consists of a standard micro-
scope (Axiophot, Zeiss, Oberkochen, Germany) fitted with a high
resolution digital camera (ProgRes 3000, Kontron Elektronik
GmbH, Eching bei München, Germany) under control of WinCam
1.4 software (CCD-Videometrie, Unterscheissheim, Germany) on a
PC computer. Images were then analysed using KS-400 2.08 soft-
ware (Kontron Elektronik). The image analysis procedure was
automated by a KS-400 macro with an individual threshold setting
for each section. Threshold setting was subjectively verified by
superimposing the contours of the obtained binary image on the
original. If detectable mismatch was found, the procedure of
thresholding was redone until matching was acceptable. Four
vascular hotspots were identified by the same procedure as for
manual counting and the CIAS was used to obtain data from each
spot at 200´ magnification (area 0.307 mm2). For each vessel in
each area, the perimeter, area, maximal diameter and minimal
diameter were measured and stored in a database. Means for each
tumour were calculated and used for further statistical analysis of
treatment groups. Frequency distributions of the vessel areas were
based on the entire database of each treatment group.
RT-PCR and in situ hybridization
The mRNA expression of VEGF was evaluated by in situ
hybridization in histological sections from four different tumours in
each treatment group and in ten controls. In situ hybridization for
VEGF was performed mainly as previously described (Lindgren et
al, 1997); however, it was modified for formalin-fixed paraffin-
embedded sections. RNA was isolated from a BT4C tumour using
TRIzol reagent (GIBCO BRL, Life Technologies, Stockholm,
Sweden) according to the instructions of the manufacturer. Specific
polymerase chain reaction (PCR) primers were selected for rat
glioma-derived VEGF. Reverse transcriptase PCR (RT-PCR) was
thereafter performed on 1 mg tumour RNA using a One Strand
cDNA synthesis kit (Boehringer Mannheim, Stockholm, Sweden)
and the reverse primer for VEGF. The cDNA synthesis was
followed by a standard PCR protocol where annealing temperature
was set to 45°C. This resulted in a PCR product of 404 bp. The
fragments were cloned into a plasmid carrying T3 and T7 DNA
polymerase promotors on opposite sides of the cloning cassette
(Bluescript SK +/–, Stratagene, La Jolla, CA, USA). The VEGF
fragment was inserted in the SmaI site of the cloning cassette.
Orientation of fragment was confirmed by restriction site analysis.
A digoxin (DIG)-labelled RNA probe was obtained by using a
DIG–RNA kit (Boehringer Mannheim, Stockholm, Sweden) and
plasmids linearized with appropriate restriction enzymes. Probes144 M Johansson et al
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were manufactured according to the vendors’ instructions and puri-
fied on NucTrap purification columns (Stratagene, La Jolla, CA,
USA).
After dewaxing in fresh xylene for at least 60 min, sections were
rehydrated through a graded ethanol series. Sections were then
fixed in 4% paraformaldehyde/77 mM Na2HPO4, 23 mM NaH2PO4,
0.15 M NaCl (PBS) for 10 min and washed in PBS 5 min ´ 2. To
facilitate probe penetration, sections were incubated in 0.2 M HCl,
washed in PBS 5 min ´ 2, acetylated for 10 min in a buffer
containing 1.33% vv triethanolamine, 0.175% vv HCl and 0.25%
acetic anhydride followed by washing in PBS 5 min ´ 2. To further
break formalin induced protein changes, sections were incubated at
37°C with proteinase K 25 mg ml-1 for 30 min and washed in PBS
5 min ´ 2. Slides were then prehybridized in 25% formamide, 5 ´
saline–sodium citrate (SSC), 5 ´ Denhardt (Sigma, Stockholm,
Sweden), 250 mg ml-1 Bakers yeast RNA and 500 mg ml-1 salmon
sperm DNA in 4°C overnight or 10 min at RT in a chamber humid-
ified with 50% formamide and 5 ´ SSC. Hybridization was
performed with DIG-labelled RNA probes at a concentration
of 50–200 ng 100 ml-1 hybridization buffer, similar to the pre-
hybridization buffer but supplemented with 10% dextransulphate.
Hybridization was carried out at 70°C overnight and sections were
protected from drying with siliconized glass coverslips (Sigmacoat,
Sigma). All incubations to this step were carried out in RNAse-free
containers and all buffers were diluted in di-ethylpyrocarbonate-
treated deionized water. Following hybridization, coverslips were
removed in 70°C 5 ´ SSC and sections were then equilibrated in
0.2 ´ SSC, 0.1 M Tris pH 7.5, 0.15 M sodium chloride (NaCl) (B1)
for 60 min. Sections were then incubated in 10% fetal calf serum
(FCS)/B1 for at least 60 min. The DIG-labelled probes were
tracked by incubating sections with anti-DIG fabs (Boehringer
Mannheim, Stockholm, Sweden), diluted 1:5000 in 1% FCS/B1,
at 4°C overnight. Development was carried out at 30°C with
75 mg ml-1 5-bromo-4-chloro-3-inolyl-phosphate (Boehringer
Mannheim, Stockholm, Sweden), 50 mg ml-1 4-nitro blue tetra-
zoliumchloride (Boeringer Mannheim, Stockholm, Sweden) in a
buffer consisting of 10% polyvinyl alcohol in 0.1 M Tris pH 9.0,
0.1 M NaCl and 5 mM magnesium chloride. Development was
stopped after 12 h by immersing slides in deionized water. Finally,
sections were mounted in gelatine glycerol medium.
The VEGF expression was semiquantitatively evaluated by two
of the authors on blinded sections. The staining was expressed as
missing, weak, moderate or pronounced.
Statistical analysis
Values are expressed as means ± s.e.m. For comparisons between
groups, the Mann–Whitney U-test was used. A P-value less than
0.05 was considered to be statistically significant. Linear regres-
sion was used for correlation of manual and CIAS-aided MVD
assessment. Statistical analysis was performed using the StatView
4.5 software (Abacus Concepts, Berkley, CA, USA) for the Power
Macintosh (Apple Computer, Cupertino, CA, USA) computer.
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Figure 1 Brain tumour volume (mm3) in control animals and animals treated
with estramustine (EaM), radiotherapy alone (RT) or radiotherapy combined
with estramustine (EaM/RT). Values are given as means ± s.e.m. *P < 0.05,
**P < 0.01 compared to control
Figure 2 MVD in intracerebral glioma expressed as vessels per mm2 in
control animals and animals treated with estramustine (EaM), radiotherapy
alone (RT) or radiotherapy combined with estramustine (EaM/RT). Values
are given as means ± s.e.m. *P < 0.05 compared to control
Table 1 Computerized image analysis of microvascular density (MVD), perimeter, area, minimum diameter and maximum diameter in treated and not treated
intracerebral rat glioma. Values given as mean ± SE
Group MVD (vessels/mm2) Perimeter (mm) Area (mm2) Min diameter (mm) Max diameter (mm)
Controls 250 ± 25 89 ± 8 145 ± 20 11 ± 0.7 22 ± 1.3
EaM 203 ± 11 129 ± 7** 352 ± 36** 15 ± 0.6** 32 ± 1.3**
EaM/RT 200 ± 14 124 ± 7* 278 ± 15** 14 ± 0.4* 31 ± 0.9**
RT 179 ± 12* 82 ± 4 115 ± 11 10 ± 0.4 21 ± 0.9
*P < 0.05, **P < 0.01 compared to control.Microvascular effects of radiotherapy and EaM 145
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RESULTS
Tumour size
The combination of EaM and radiotherapy decreased tumour
volume significantly and was the most effective treatment admin-
istered in this experiment when compared to controls (Figure 1).
EaM/RT treatment reduced the tumour volume to 69 ± 12 mm3
compared to a volume of 185 ± 13 mm3 in the control group
(P < 0.01). EaM alone also decreased tumour volume but to a
lower degree than the combination treatment (117 ± 18 mm3;
P < 0.05). Radiotherapy alone caused a small decrease in tumour
volume (143 ± 15), which was not significant in this experiment.
Microvascular density
When MVD was manually assessed, radiotherapy alone signifi-
cantly decreased mean MVD to 157 ± 14 vessels per mm2
compared to controls where mean MVD was found to be 217 ± 22
vessels per mm2 (P < 0.05) (Figure 2). EaM, when given alone, did
not affect tumour MVD (195 ± 12 vessels per mm2) and, interest-
ingly, when EaM was given in combination with RT no reduction
in tumour MVD could be observed (205 ± 13 vessels per mm2).
MVD assessed by computerized image analysis showed reason-
able correlation to the manually obtained data (r = 0.65) and radio-
therapy was also found to decrease MVD (P < 0.05) when
analysed with CIAS (Table 1).
Microvessel size
Individual tumour vessel size increased significantly when EaM
was administered (Table 1). Mean vessel area, perimeter and
diameter all increased significantly in the EaM and EaM/RT
groups. The distribution of individual vessel area for the different
treatment groups is shown in frequency distribution histograms in
Figure 3.
VEGF in situ hybridization
A high expression of VEGF mRNA was found in the invasive
tumour border in all groups (Figure 4A) while the expression was
mostly absent in the centre of the tumours (Figure 4B). However, 5
days after completion of radiotherapy we found an increased cellular
expression of VEGF scattered in the tumour centre (Table 2).
DISCUSSION
This study demonstrated that the tumoural vascular network is
significantly affected by fractionated irradiation with a decrease in
microvessel density. EaM seems to abolish this effect concomitant
with an enhanced anti-tumoural effect. Since tumour vasculariza-
tion is of utmost importance for tumour progression, it is
suggested that the anti-vascular effect of irradiation may be partly
involved in the anti-tumoural effect of radiotherapy. On the other
hand, an impaired tumoural vascular network may reduce
oxygenation and thus give a negative effect on tumour cell
damage. Therefore, the vascular effect demonstrated may be a
radiobiological Janus face where decreased oxygenation may
outnumber the possible positive treatment effects on tumour
growth through the vascular damage. In this sense the effect of
EaM can be of therapeutic interest.
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The effect of radiotherapy on normal tissue vasculature is well
known and believed to be the main cause of late radiation damage
(Baker and Krochak, 1989). The slow turnover rate of non-prolif-
erating endothelial cells leads to delayed damage to the vascula-
ture. However, the effect on tumour vasculature may be different.
The rapid turnover rate of proliferating endothelial cells in the
tumour stroma (Denekamp and Hobson, 1982) make them poten-
tially more vulnerable to irradiation than normal tissue and, there-
fore, it has been hypothesized that tumour stroma may be an
important target for radiotherapy (Denekamp, 1991). Our study
supports this hypothesis. Since no acute effects on the expression
of VEGF in tumour tissue during irradiation could be demon-
strated, the anti-vascular effect may well be mediated by direct
antiproliferative effects on the endothelial cells. The elevated
expression of VEGF in the central tumour demonstrated 5 days
after radiotherapy may be induced by an increased oxygen demand
in the tissue where angiogenesis was hampered by irradiation.
Hypoxia is known to be the most important physiological stimuli
for VEGF up-regulation in vitro (Shweiki et al, 1992) as well as in
vivo (Plate et al, 1992, 1993).
A
B
C
D
E
Figure 4 VEGF in situ hybridization demonstrating the high expression in
tumour border in control animals (A) and no expression in tumour centre (B)
of the same control tumour. Also in the radiotherapy group, a high VEGF
expression in the tumour border is seen (C) but, in the tumour centre of
irradiated tumours, clusters of VEGF-expressing cells indicate a picture
different from controls (D). Factor VIII immunohistochemistry of a vascular
hotspot in a control animal where mean microvascular density is 252 vessels
per mm2 (E)Microvascular effects of radiotherapy and EaM 147
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The effect of radiotherapy on tumour angiogenesis, however,
has been less extensively studied. In tumour tissue most experi-
mental studies have focused on the functional vasculature. A
decrease of functional tumour vessels, days to weeks after single-
dose irradiation, has been reported in a mouse mamary carcinoma
model (Hilmas and Gillette, 1975) as well as in a human
melanoma xenograft (Solesvik et al, 1984). In other studies, an
initial increase in functional tumour vessels followed by decrease
was reported in a mouse neuroblastoma after single-dose irradia-
tion (Song et al, 1974) and in a rat rhabdomyosarcoma during frac-
tionated radiotherapy (Zywietz, 1990). The increase of functional
tumour vessels shortly after irradiation has also been reported
(Rubin and Casarett, 1966; Dewhirst et al, 1990). The supervascu-
larized state in at least some regressing tumours is believed to be
due to a relative increase of the tumour stromal compartment
rather than increased tumour angiogenesis. In models of experi-
mental angiogenesis, single-dose radiotherapy has been shown to
inhibit in vivo angiogenesis in the chick embryo chorioallantoic
membrane (CAM) assay (Hatjikondi et al, 1996) as well as in the
disc angiogenesis model in the rat (Prionas et al, 1990).
Most studies, although using other techniques, are in concordance
with our results and further validate the finding that irradiation may
inhibit tumour angiogenesis. To our knowledge, the effect of frac-
tionated radiotherapy on the MVD in experimental tumours has not
previously been described quantitatively using an endothelium-
specific marker. Interestingly, a limited clinical study indicates that
preoperative radiotherapy may decrease intratumoural vascular
density in patients with malignant glioma (Seiler et al, 1979).
EaM has previously been shown to have radiosensitizing effects
in vitro (Yoshida et al, 1994; Bergenheim et al, 1995) as well as in
vivo (Bergenheim et al, 1995). The mechanism has been coupled
to the ability of EaM to block tumour cells in the vulnerable G2/M
phase of the cell cycle (von Schoultz et al, 1988). The radiosensi-
tizing effect of EaM is more pronounced in vivo than in vitro, an
observation that suggests that other mechanisms, such as vascular
effects, are of importance. Earlier, we showed that EaM increases
tumour blood flow (TBF) in the BT4C rat glioma model
(Johansson et al, 1997). In this study EaM reduced the anti-angio-
genic effect of radiotherapy and potentiated the treatment effects
as previously shown. The increase in TBF, together with the vaso-
radioprotective effects seen in this study, may be a physiological
mechanism by which EaM acts as a radiosensitizer. It is well-
established that tumour hypoxia is an important cause of radio-
resistance (Hall, 1994) and EaM may act as a radiosensitizer
through enhancement of tumour oxygenation.
The mechanism by which EaM reduces the negative effects of
irradiation on tumour angiogenesis is not known. Estradiol, one of
the components of the EaM conjugate, is known to promote prolif-
eration and migration of human umbilical vein cells in vitro
(Morales et al, 1995). Estradiol has also been shown to up-regulate
VEGF mRNA in normal endometrium (Cullinan Bove and Koos,
1993) as well as in a chemically induced rat mammary carcinoma
(Nakamura et al, 1996). An increase of VEGF protein, as well as
increased MVD and tumour vessel size 7 days after estradiol treat-
ment, has been reported in an estradiol-induced rat pituitary
tumour model (Banerjee et al, 1997). One mechanism by which
estradiol may act on tumour vasculature could, therefore, be the
induction of the VEGF system. In our study we could not confirm
any increase in VEGF expression after EaM treatment. However,
based on this study, altered expression of VEGF or any other
angiogenic factor cannot be excluded as the mechanism by which
EaM protects irradiated tumour vasculature.
Although in a totally different tumour model, our findings that
an estradiol-based cytotoxic conjugate induces increased TBF and
increased mean vessel size suggests that similar oestrogen-related
mechanisms to those in the pituitary model may be involved. This
is supported by the fact that estradiol alone also increases TBF in
the BT4C rat glioma model (Johansson et al, 1997). The increased
mean vessel size after EaM treatment seen in this experiment may
be due to an induction of tumour vessel growth or a tumoural
vasodilatation which could explain the previously reported
increase in TBF. The levels of free estradiol in tumour tissue after
EaM treatment are low but may be sufficient to induce growth and
dilatation or enlargement of tumour microvasculature in irradiated
tumours (Johansson et al, 1998). In the clinical situation, estradiol
levels are at least high enough to induce the oestrogenic side-
effects recognized after treatment with estramustine phosphate
(Bergenheim et al, 1996). Another explanation could be that the
intact EaM conjugate exerts estradiol-like actions when it comes
to modulating TBF and neovascularization. Somewhat puzzling,
however, EaM did not increase tumour MVD in non-irradiated
tumours. Maybe the vascular density in these tumours is so high
that the angiogenesis cascades are saturated, and only when angio-
genesis is suppressed, is there space for increased tumour MVD.
In the present study, quantification of vascularization was
performed by manual counting of vessels and aided by a CIAS. The
correlation between the methods was found to be acceptable and
both methods displayed the same differences between treatment
groups. There are two possible explanations for the absolute differ-
ences in MVD counts (Figure 2 and Table 1) are two. First, perfect
correlation cannot be expected since the two measurements were
not performed on the very same subjectively chosen vascular hot
spots. Second, due to technical limitations (camera CCD element
size), the area analysed using the CIAS was only one-quarter of the
Table 2 The expression of VEGF detected by in situ hybridization in the border and centre of malignant rat glioma. Staining quantified
in a four-graded scale where 0 = no staining; 1 = weak staining; 2 = moderate and 3 = intensive staining
Staining intensity
Tumour border Tumour centre
0123 0 1 2 3
Controls (n = 5) 0 1 1 3 2 3 0 0
EaM (n = 4) 0 0 3 1 0 4 0 0
EaM/RT (n = 4) 0 1 3 0 1 3 0 0
RT (n = 4) 0 0 3 1 0 2 1 1148 M Johansson et al
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area counted manually. This is believed to increase measurement
scatter since the optimal counting area is larger. Taking this into
consideration, we believe that the correlation between the methods
is good and further validates the findings reported. In this study,
computerized colour image analysis was used as a complement to
manual counting, but the results reported encourage further refine-
ment of the method. Moreover, the CIAS proved powerful in
providing individual vessel size data.
To conclude, this study demonstrates that fractionated radio-
therapy inhibits tumour angiogenesis in a rat glioma model. This may
be a part of the treatment effect of radiotherapy. However, the
decrease in vascularization could make drug delivery to tumours
even more difficult post-irradiation. Interestingly, the estradiol-linked
cytotoxic agent, EaM, concomitantly counteracted the anti-angio-
genic effects of radiotherapy and increased the irradiation-induced
growth inhibition. Therefore, this study suggests that the treatment
schedule is important when combining radiotherapy with other treat-
ment modalities such as chemotherapy.
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